Hosted on MSN1mon
FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatmentThe company states: “Eisai (ESAIY) and Biogen (BIIB) announced that the FDA ... LEQEMBI is indicated for the treatment of Alzheimer’s disease – AD – in patients with Mild Cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback